CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging

Pijnenburg, Y. A. L.; Schoonenboom, S. N. M.; Barkhof, F.; Knol, D. L.; Mulder, C.; van Kamp, G. J.; von Swieten, J. C.; Scheltens, P.
February 2006
Journal of Neurology, Neurosurgery & Psychiatry;Feb2006, Vol. 77 Issue 2, p246
Academic Journal
In order to better understand the large variation in cerebrospinal fluid (CSF) tau and amyloid-beta(1–42) (Aβ42) in frontotemporal lobar degeneration (FTLD), relations between these biomarkers and clinical parameters, neuroimaging characteristics, and apolipoprotein E (ApoE) genotype were studied in 31 patients with FTLD, including 16 patients with the frontal variant and 15 with the temporal variant. CSF tau was highest in FTLD with predominant temporal involvement. In the frontal subgroup, CSF tau level was influenced by the number of ApoE ∈3 alleles. In the temporal subgroup, CSF tau level was dependent on a combination of CSF Aβ42, age, disease duration, and disease severity. No relation with degree of atrophy or asymmetry on neuroimaging could be established. CSF Aβ42 variability remained unexplained. Future research could study the role of ApoE genotype and Aβ42 in FTLD, as well as establish measures for disease intensity.


Related Articles

  • TOMM40 poly-T Variants and Cerebrospinal Fluid Amyloid Beta Levels in the Elderly. Pomara, Nunzio; Bruno, Davide; Nierenberg, Jay; Sidtis, John; Martiniuk, Frank; Mehta, Pankaj; Zetterberg, Henrik; Blennow, Kaj // Neurochemical Research;Jun2011, Vol. 36 Issue 6, p1124 

    variable poly-T polymorphism in the TOMM40 gene, which is in linkage disequilibrium with APOE, was recently implicated with increased risk and earlier onset age for late-onset Alzheimer's disease in APOE ε3 carriers. To elucidate potential neurobiological mechanisms underlying this...

  • The Role of Apolipoprotein E (APOE) Genotype in Early Mild Cognitive Impairment (E-MCI). Risacher, Shannon L.; Sungeun Kim; Li Shen; Kwangsik Nho; Foroud, Tatiana; Green, Robert C.; Petersen, Ronald C.; Jack Jr., Clifford R.; Aisen, Paul S.; Koeppe, Robert A.; Jagust, William J.; Shaw, Leslie M.; Trojanowski, John Q.; Weiner, Michael W.; Saykin, Andrew J. // Frontiers in Aging Neuroscience;Mar2013, p1 

    Objective: Our goal was to evaluate the association APOE with amyloid deposition, cerebrospinal fluid levels (CSF) of Aβ, tau, and p-tau, brain atrophy, cognition and cognitive complaints in E-MCI patients and cognitively healthy older adults (HC) in the ADNI-2 cohort. Methods: 209 E-MCI and...

  • Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Wahrle, Suzanne E.; Shah, Aarti R.; Fagan, Anne M.; Smemo, Scott; Kauwe, John S. K.; Grupe, Andrew; Hinrichs, Anthony; Mayo, Kevin; Hong Jiang; Thal, Leon J.; Goate, Alison M.; Holtzman, David M. // Molecular Neurodegeneration;2007, Vol. 2, p1 

    Background: Animal studies suggest that brain apolipoprotein E (apoE) levels influence amyloid- β (Aβ) deposition and thus risk for Alzheimer's disease (AD). We have previously demonstrated that deletion of the ATP-binding cassette A1 transporter (ABCA1) in mice causes dramatic reductions...

  • CSF Apo-E levels associate with cognitive decline and MRI changes. Toledo, Jon; Da, Xiao; Weiner, Michael; Wolk, David; Xie, Sharon; Arnold, Steven; Davatzikos, Christos; Shaw, Leslie; Trojanowski, John // Acta Neuropathologica;May2014, Vol. 127 Issue 5, p621 

    Apolipoprotein E ( APOE) ε4 allele is the most important genetic risk factor for Alzheimer's disease (AD) and it is thought to do so by modulating levels of its product, apolipoprotein E (Apo-E), and regulating amyloid-β (Aβ) clearance. However, information on clinical and biomarker...

  • Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. Rösler, N.; Wichart, I.; Jellinger, K. A. // Journal of Neural Transmission;Feb2001, Vol. 108 Issue 2, p231 

    Summary. Immunoreactivities of total apolipoprotein E (ApoE-IR), amyloid β peptide(1–42) (Aβ42-IR), interleukin-6 (IL-6-IR), substance P (SPIR) and total τ protein (TTIR) were measured in lumbar cerebrospinal fluid samples of patients with Alzheimer's disease (AD),...

  • Do CSF levels of t-Tau, p-Tau and β amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A I-FP-CIT study in the early stages of the disease. Chiaravalloti, Agostino; Stefani, Alessandro; Fiorentini, Alessandro; Lacanfora, Annamaria; Stanzione, Paolo; Schillaci, Orazio // European Journal of Nuclear Medicine & Molecular Imaging;Nov2014, Vol. 41 Issue 11, p2137 

    Purpose: To investigate the relationships among cerebrospinal fluid (CSF) levels of t-Tau, p-Tau and Aβ amyloid peptide and I-FP-CIT uptake. Methods: The study included 58 subjects (31 men and 27 women, age 67 ± 9 years) with a clinical diagnosis of Parkinson disease diagnosed according to...

  • Towards compendia of negative genetic association studies: an example for Alzheimer disease. Blomqvist, Mia E. L.; Reynolds, Chandra; Katzov, Hagit; Feuk, Lars; Andreasen, Niels; Bogdanovic, Nenad; Blennow, Kaj; Brookes, Anthony J.; Prince, Jonathan A. // Human Genetics;Mar2006, Vol. 119 Issue 1/2, p29 

    Most genetic sequence variants that contribute to variability in complex human traits will have small effects that are not readily detectable with population samples typically used in genetic association studies. A potentially valuable tool in the gene discovery process is meta-analysis of the...

  • Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer’s disease: A multicenter assessment. BLENNOW, K.; DE MEYER, G.; HANSSON, O.; MINTHON, L.; WALLIN, A.; ZETTERBERG, H.; LEWCZUK, P.; VANDERSTICHELE, H.; VANMECHELEN, E.; KORNHUBER, J.; WILTFANG, J. // Journal of Nutrition, Health & Aging;Mar2009, Vol. 13 Issue 3, p205 

    To better understand the seemingly contradictory plasma β-amyloid (Aβ) results in Alzheimer’s disease (AD) patients by using a newly developed plasma Aβ assay, the INNO-BIA plasma Aβ forms, in a multicenter study. A combined retrospective analysis of plasma Aβ isoforms on...

  • Cerebrospinal fluid biomarkers for Alzheimer's disease: the role of apolipoprotein E genotype, age, and sex. Mehrabian, Shima; Alexopoulos, Panagiotis; Ortner, Marion; Traykov, Latchezar; Grimmer, Timo; Kurz, Alexander; Förstl, Hans; Bickel, Horst; Diehl-Schmid, Janine // Neuropsychiatric Disease & Treatment;Dec2015, Vol. 11, p3105 

    Introduction: Cerebrospinal fluid (CSF) biomarkers improve the diagnostic accuracy for Alzheimer's disease (AD), even at the predementia stage of the disease. The ε4-allele of apolipoprotein E (ApoE ε4), female sex, and older age are well-known risk factors for AD. It is unclear how these...


Read the Article


Sign out of this library

Other Topics